# A Study of Sofosbuvir and Ledipasvir From Magicbuvir Plus 90/400 mg Tablets (Magic Pharma, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)

> **NCT03005210** · PHASE1 · COMPLETED · sponsor: **Genuine Research Center, Egypt** · enrollment: 37 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Magicbuvir Plus
- **DRUG:** Harvoni (fist dose)
- **DRUG:** Harvoni (second dose)

## Key facts

- **NCT ID:** NCT03005210
- **Lead sponsor:** Genuine Research Center, Egypt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2016-11
- **Final completion:** 2016-12
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2016-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03005210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03005210, "A Study of Sofosbuvir and Ledipasvir From Magicbuvir Plus 90/400 mg Tablets (Magic Pharma, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03005210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*